13 completed, 10 terminated, 2 unknown, 2 withdrawn. 28 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 13, Terminated 10, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 7 | Completed 2, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation Eculizumab - Kidney Transplantation | Phase 1 / Phase 2 | Unknown | Tao Lin | 30 | 2024-07-01 | 2024-06-13 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy Eculizumab, Ravulizumab, BCX9930 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | BioCryst Pharmaceuticals | 12 | 2021-12-06 | 2025-03-07 |
| Complement Regulation to Undo Systemic Harm in Preeclampsia Eculizumab - Preeclampsia, Severe Preeclampsia | Phase 2 | Terminated | Cedars-Sinai Medical Center | 2 | 2021-09-13 | 2023-11-29 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Eculizumab - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 23 | 2018-08-03 | 2023-09-21 |
| Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Danicopan, Eculizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 12 | 2018-05-08 | 2023-12-12 |
| Complement Inhibitor Eculizumab in Clinical Islet Transplantation Eculizumab - Diabetes Mellitus | Phase 2 | Completed | Uppsala University | 3 | 2016-05-15 | 2018-10-04 |
| Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation Eculizumab - Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation | Phase 1 / Phase 2 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2015-02-01 | 2025-11-20 | |
| Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) Eculizumab, Placebo - Delayed Graft Function | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 288 | 2014-08-21 | 2018-12-17 |
| Eculizumab in Primary MPGN Eculizumab - Membranoproliferative Glomerulonephritis | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2014-03-01 | 2018-01-17 |
| Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Eculizumab, Immunoglobulin, Plasmapheresis - Antibody-mediated Rejection, Humoral Rejection | Phase 2 | Terminated | Brigham and Women's Hospital | 11 | 2013-11-01 | 2017-09-21 |
| Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation Eculizumab, Normal Saline - Delayed Graft Function, Kidney Transplantation | Phase 2 | Terminated | Heeger, Peter, M.D. | 21 | 2013-08-01 | 2018-02-27 |
| Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury eculizumab - End-Stage Renal Disease, Kidney Failure | Phase 2 | Completed | Russian Academy of Medical Sciences | 57 | 2012-09-01 | 2018-08-31 |
| Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor Eculizumab - Stage V Chronic Kidney Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 80 | 2012-08-29 | 2019-05-03 |
| An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Eculizumab - Chronic Hemolysis | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 5 | 2012-02-01 | 2012-04-18 |
| A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant Eculizumab, Placebo - Delayed Function of Renal Transplant | Phase 2 | Terminated | Schroppel, Bernd, M.D. | 8 | 2011-12-01 | 2019-05-06 |
| Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization Eculizumab - Antibody Mediated Rejection | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 102 | 2011-11-02 | 2017-10-03 |
| Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Standard of care treatment, eculizumab - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2011-05-01 | 2017-02-23 | |
| Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 6 | 2010-05-01 | 2015-07-20 |
Showing 20 of 28. Sign in to see all of them.
Hemoglobinuria, Paroxysmal (5) · Delayed Graft Function (3) · Kidney Failure, Chronic (2) · Neuromyelitis Optica (2) · Rejection, Psychology (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Antiphospholipid Syndrome (1) · Atypical Hemolytic Uremic Syndrome (1) · Demyelinating Diseases (1) · Diabetes Mellitus (1) · Geographic Atrophy (1) · Glomerulonephritis, Membranoproliferative (1) · HELLP Syndrome (1) · Infections (1) · Macular Degeneration (1)
Alexion Pharmaceuticals, Inc. (8) · Mayo Clinic (3) · Assistance Publique - Hôpitaux de Paris (1) · BioCryst Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Cedars-Sinai Medical Center (1) · Children's Hospital Medical Center, Cincinnati (1) · Hadassah Medical Organization (1) · Heeger, Peter, M.D. (1) · Johns Hopkins University (1) · Mario Negri Institute for Pharmacological Research (1) · Mark Stegall (1) · NovelMed Therapeutics (1) · Philip J. Rosenfeld, MD, PhD (1) · Russian Academy of Medical Sciences (1)
United States (17) · Italy (7) · Spain (5) · United Kingdom (5) · France (4) · Australia (3) · Canada (3) · Germany (3) · Sweden (3) · Brazil (1) · China (1) · Czechia (1) · Hungary (1) · Israel (1) · Japan (1)
Anil K Chandraker, MD (1) · Austin G Kulasekararaj, MBBS, MD (1) · Benjamin Philosophe, MD, PHD (1) · Bernd Schroppel, MD (1) · Dror Mevorach, MD (1) · Gunnar Tufveson, MD, PhD (1) · Mark D Stegall (1) · Mark D. Stegall, M.D. (1) · Mark Stegall, MD (1) · Masayo Ogawa, MD (1) · Michael M Kaabak, MD (1) · Patrick H Nachman, MD (1) · Peter S Heeger, MD (1) · Philip J Rosenfeld, MD, PhD (1)
PMID 21222185, PMID 21942930, PMID 23512355, PMID 23623397, PMID 23934275, PMID 24289920, PMID 24354307, PMID 24408973, PMID 24990476, PMID 27568864, PMID 30887675, PMID 32990324, PMID 34314483, PMID 37314061, PMID 37946262, PMID 42763038
2014 (1), 2016 (1), 2019 (1), P01DK058335 (1), UL1TR000135 (1)